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LRIG2 Mutations Cause Urofacial Syndrome
Helen M. Stuart,1 Neil A. Roberts,1,2 Berk Burgu,4 Sarah B. Daly,1 Jill E. Urquhart,1 Sanjeev Bhaskar,1
Jonathan E. Dickerson,1 Murat Mermerkaya,4 Mesrur Selcuk Silay,6 Malcolm A. Lewis,2
M. Beatriz Orive Olondriz,7 Blanca Gener,8 Christian Beetz,9 Rita E. Varga,9 O¨mer Gu¨lpınar,4
Evren Su¨er,4 Tarkan Soygu¨r,4 Zeynep B. O¨zc¸akar,4 Fatosx Yalc¸ınkaya,5 Aslı Kavaz,5 Burcu Bulum,5
Adnan Gu¨cu¨k,10 Wyatt W. Yue,11 Firat Erdogan,12 Andrew Berry,3 Neil A. Hanley,3
Edward A. McKenzie,13 Emma N. Hilton,1 Adrian S. Woolf,2,14 and William G. Newman1,14,*
Urofacial syndrome (UFS) (or Ochoa syndrome) is an autosomal-recessive disease characterized by congenital urinary bladder dysfunc-
tion, associated with a significant risk of kidney failure, and an abnormal facial expression upon smiling, laughing, and crying.We report
that a subset of UFS-affected individuals have biallelic mutations in LRIG2, encoding leucine-rich repeats and immunoglobulin-like
domains 2, a protein implicated in neural cell signaling and tumorigenesis. Importantly, we have demonstrated that rare variants in
LRIG2 might be relevant to nonsyndromic bladder disease. We have previously shown that UFS is also caused by mutations in
HPSE2, encoding heparanase-2. LRIG2 and heparanase-2 were immunodetected in nerve fascicles growing between muscle bundles
within the human fetal bladder, directly implicating both molecules in neural development in the lower urinary tract.Lower-urinary-tract (LUT) and/or kidney malformations
occur in 1–2 out of 1,000 pregnancies and are common
causes of childhood renal failure.1 Advances have been
made regarding genetic causes of kidney malformations,2
but less is known about LUT malformations despite the
fact that some, including nonsyndromic vesicoureteric re-
flux (VUR), are common and familial.3 Autonomic nerve
activity controls the bladder’s ability to act as a low-pres-
sure reservoir, which intermittently and completely expels
its contents per urethra.4 Several congenital disorders
feature dysfunctional bladders. Bladder muscle is weak in
prune belly syndrome (PBS [MIM 100100]), a condition
sometimes associated with mutation of CHRM3 (MIM
118494), encoding the M3 receptor that mediates detrusor
contraction.5 In urofacial syndrome (UFS [MIM 236730]),
or Ochoa syndrome, detrusor muscle is overactive yet fails
to fully expel urine because of concomitant internal
sphincter contraction.6 Individuals with PBS and UFS can
experience lifelong urinary incontinence, recurrent uro-
sepsis, VUR, and kidney failure.5–7 In addition, some indi-
viduals with UFS have severe constipation, indicating
a generalized elimination defect.
In 2010, biallelic, loss-of-function mutations in HPSE2
(MIM 613469) were identified as causing UFS.8,9 HPSE2
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The Americinhibits heparanase-1 activity.10 HPSE2 mutations were
not detected in all UFS cases,8 consistent with genetic
heterogeneity. Accordingly, after institutional ethical
review and approval (University of Manchester [06138]
and National Health Service ethics committees [06/
Q1406/52 and 11/NW/0021]) and written informed
consent, copy-number analysis and autozygosity mapping
(in consanguineous families only) were performed with
the Affymetrix SNP 6.0 array, as previously described,8
and genotype calling was carried out with AutoSNPa.11
We performed whole-exome capture (Agilent SureSelect
38 Mb) followed by massively parallel sequencing (Illu-
mina HiSeq2000) on two such unrelated individuals (IV:2
from family 1 and II:1 from family 2). Over 3 Gb of
sequence was generated for each subject. Reads were
aligned with the human reference genome version
GRCh37/Hg19, and >73% of the targeted exome was rep-
resented by at least 10-fold coverage. Single-nucleotide
substitutions and small insertion and/or deletion variants
were identified with our in-house variant-calling pipeline
(Table S1, available online), and exome variant profiles
were analyzed with a model of a rare autosomal-recessive
disorder. In the same gene in both individuals, we priori-
tized rare putative loss-of-function variants that were
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Figure 1. Identification of Mutations in LRIG2 in Three Families Affected by UFS
Pedigrees and LRIG2 mutation analysis in families 1 (A), 2 (B), and 3 (C).
(A) In family 1, a homozygous frameshift (c.1230delA [p.Glu410Aspfs*6]) in exon 10 was identified.
(B) In family 2, affected child II-I is shown at the age of 6months. Her voiding cystourethrogram shows a trabeculated bladder and severe
left-sided VUR (Bi). A compound-heterozygous frameshift (c.2088delC [p.Ser697Hisfs*11]) (Bii) and a compound-heterozygous
(legend continued on next page)
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137 and the National Heart, Lung, and Blood Institute
(NHLBI) Exome Variant Server (EVS, ESP6500). Putative
pathogenic variants were confirmed by Sanger sequencing.
PCR amplification of genomic DNA was performed with
primers designed to cover the exon and intron-exon
boundaries with NCBI Primer BLAST (Table S2). Direct
sequencing was performed with the ABI BigDye Termi-
nator v.3.1 cycle sequencer system (Applied Biosystems)
on an ABI 3730 sequencer.
In family 1 (Figure 1A), IV:2 is an 8-year-old Turkish girl
with facial features of UFS (Figure S1), and she is the second
child of consanguineous parents. At the age of 5 years, she
presented with urosepsis and constipation. Investigations
revealed a low-capacity, overactive bladder, as well as bilat-
eral VUR, hydronephrosis, andmild renal impairment. She
was treated with intermittent catheterization, antimuscar-
inic drugs, and surgical bladder augmentation; however,
despite these treatments, renal failure progressed, and
she is about to start peritoneal dialysis. Autozygosity
mapping, undertaken with Affymetrix v.6.0 SNP arrays as
previously described,8 revealed in 1p13.2 a 52Mb homozy-
gous region containing 577 coding genes; she shares this
region with her younger brother (IV:3, Figure S1). At 5
years old, he was recognized to have facial features of
UFS but had no urinary-tract symptoms. His urinary tract
was normal as assessed by ultrasound and uroflowmetry.
Invasive micturating cystourethrogram and urodynamic
studies were not undertaken because he remains asymp-
tomatic. Such phenotypic variability has been reported
previously in families affected by UFS12 such that some
affected individuals had only the facial or urinary tract
phenotype. The varied expression might be accounted
for by genetic modifiers or environmental factors, either
intrauterine or postnatal, that remain to be identified.
Within the 1p13.2 chromosomal region, exome
sequencing identified a homozygous single-base-pair dele-
tion resulting in a frameshift in exon 10 of LRIG2 (MIM
608869): c.1230delA (p.Glu410Aspfs*6) (RefSeq accession
number NM_014813.1). This deletion was confirmed by
Sanger sequencing (Figure 1A) and segregated with the
disease. The mutation was absent from variome databases,
116 local exomes, and 94 healthy Turkish controls.
Exome sequencing was also performed on a 5-year-old
Spanish girl (II:1 from family 2; Figure 1B) of nonconsan-
guineous parents. She is one of a pair of dizygotic twins
conceived after intracytoplasmic sperm injection. Mega-
cystis was visualized on ultrasonography in late gestation.
An abnormal smile was noted at 6 months of age, when
investigations revealed an overactive, trabeculated bladder
and left-sided VUR. Her course was complicated by urosep-
sis and constipation, and she was treated with intermittent
catheterization and anticholinergic drugs. In this child,AluYa5-like insertion (c.1980_1981ins371, GenBank JX891452) (Biii
present in I:2, II:1, and II:2, and sequencing of cDNA confirmed the
(C) In family 3, a homozygous nonsense mutation in exon 15 (c.21
LRIG2 variants are indicated by an asterisk. The mutations segregate
The Americexome and Sanger sequencing identified a heterozygous
frameshift mutation, c.2088delC (p.Ser697Hisfs*11),
in exon 15 and a heterozygous insertion, c.1980_
1981ins371 (GenBank JX891452), in exon 14 of LRIG2
(Figure 1B). The insertion was defined as the antisense
insertion of an Alu element with homology to AluYa5.
Sequencing of lymphocyte cDNA determined that the
insertion resulted in a transcript that skips exon 14 and
that is not subject to nonsense-mediated decay (NMD)
(Figure 1B). Lymphocyte RNA from family members was
extracted with the PAXgene blood RNA system (QIAGEN).
Reverse transcription and PCR amplification of LRIG2
cDNA were performed with the SuperScript III one-step
RT-PCR system (Life Technologies) and specific primers
(Table S2).
A second consanguineous Turkish family (family 3;
Figure 1C) has two siblings affected by UFS. II:1 is a 9-
year-old girl with facial features of UFS (Figure S1) and con-
stipation. At 4 years old, she presented with urosepsis and
enuresis when a low-capacity, overactive bladder and bilat-
eral VUR were detected. At the age of 6 years, she under-
went a left nephrectomy for Wilms tumor.13 At the age
of 2 years, her younger sister, II:2, presented with enuresis
and a low-capacity, overactive bladder and VUR and subse-
quently underwent bladder augmentation. Autozygosity
mapping identified in chromosomal region 1p13.2 a 8.5
Mb segment overlapping that in family 1, and Sanger
sequencing of LRIG2 identified homozygous nonsense
mutation c.2125C>T (p.Arg709*) in exon 15. This muta-
tion segregated with the disease in the family and was
absent from variome databases, 116 local exomes, and 94
healthy Turkish controls. Previous studies have implicated
the loss of a 1 Mb locus in chromosomal region 1p13 in
Wilms tumor,14 but LRIG2 lies outside the critical region.
The identified nonsense and frameshift LRIG2mutations
were predicted to result in loss of function via NMDof tran-
scripts. cDNA analysis showed that the large insertion
within exon 14 of family 2 results in an in-frame skipping
of this exon from the transcript; this is likely due to disrup-
tion of exon splice enhancers, consistent with the effects
of previously reported exonic insertions of AluYa5
elements.15 The transcript was not subject to NMD but
was predicted to result in loss of most of the second immu-
noglobulin (Ig)-like domain andmost conserved part of the
gene within the LRIG family (Figure S2).16 Despite some-
what variable LUT phenotypes, there were no consistent
clinical differences between these UFS individuals with
LRIG2 mutations and those previously reported to have
HPSE2 mutations.8 At present, it is difficult to draw
a conclusion about the relative contribution of each gene
to UFS. To date, of the 14 families affected by classical
UFS, we identified nine (64.3%) with mutations in HPSE2,) were identified. Gel electrophoresis demonstrated a larger band
heterozygous skipping of exon 14 in the same individuals.
25C>T [p.Arg709*]) was identified. All individuals genotyped for
d in the three families consistently with the phenotype.
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Figure 2. Identification of Mutations in LRIG2 in an Individual
with Nonsyndromic Dysfunctional Voiding
Pedigree and LRIG2 mutation analysis in this family revealed
compound heterozygous missense mutations, c.1648C>T
[p.Arg550Cys] (exon 13) and c.2554A>T [p.Ile852Phe] (exon
16), in affected individual II:1.three (21.4%) with mutations in LRIG2, and two (14.3%)
with mutations in neither gene. Other groups have only
reported individuals with mutations in HPSE2.9
Bladder dysfunction in UFS is similar to that found in
Hinman syndrome, or ‘‘non-neurogenic neurogenic
bladder.’’17,18 Accordingly, we screened LRIG2 in 23 indi-
viduals (13 multiethnic British and 10 previously reported
Turkish cases) with Hinman syndrome.19 Of these, variants
in LRIG2 were found in a single individual, a white British
male who, at the age of 10 years, presented with a 2 year
history of secondary enuresis. He was hypertensive and
had mild renal impairment. Investigations revealed a
trabeculated bladder with a thickened wall and bilateral
severe hydronephrosis. A micturating cystourethrogram
showed no obstruction, and urodynamic analysis
revealed a poorly compliant bladder with detrusor overac-
tivity and detrusor sphincter dyssynergia. Renal failure
progressed despite bladder augmentation. He lacks the
facial features of UFS. He has compound heterozygous mis-
sense variants c.1648C>T (p.Arg550Cys) (exon 13) and
c.2554A>T (p.Ile852Phe) (exon 16, Figure 2). c.1648C>T
(p.Arg550Cys) is reported in the EVS as a rare variant262 The American Journal of Human Genetics 92, 259–264, February(2 in 8,600 European American alleles), whereas
c.2554A>T (p.Ile852Phe) is not present in the EVS but is
reported in dbSNP (minor allele frequency ¼ 0.003).
Both the 550 and 852 residue positions are conserved to
Tetraodon (Figure S2). The in silico tool PolyPhen-2 pre-
dicted that both variants are damaging (0.99), and SIFT
predicted that both are most likely deleterious. LRIG pro-
teins share a domain structure with 15 leucine-rich repeats,
three Ig-like domains, a transmembrane domain, and a
cytoplasmic tail.16,20 The crystal structure of LRIG2 is not
determined, but Arg550 resides in the first Ig-like domain
of the extracellular milieu and is orthologous to an exper-
imentally determined structure from murine LRIG3; it
has >50% sequence identity to LRIG2 in this region
(Figure S3). Probably, this substitution disrupts oligomer
formation of the Ig domains. The Ile852 residue is located
in the cytoplasmic exposed region, close to the predicted
transmembrane helix (amino acids 808–830). Its function,
as well as its mutation consequence, is less predictable as a
result of a lack of structural information. Screening of
LRIG2 in further individuals with nonsyndromic voiding
dysfunction will be required for establishing the contribu-
tion of this gene to this broader phenotype.
LRIG2 modulates cell turnover and adhesion in neural
support cells via altered growth-factor signaling,21 and
altered LRIG2 localization occurs in various types of neural
tumors.22–24 Detection of LUT abnormalities antenatally
and abnormal grimacing in infancy implies that patho-
genic mechanisms underlying UFS initiate during develop-
ment. Indeed, in embryonic mice, VII nerve ganglia
express Lrig2.16 The human bladder initiates at 7 weeks
of gestation.5,25 At this stage, we detected by immunohis-
tochemistry neither LRIG2 nor heparanase-2 (data not
shown). Later in the first trimester, detrusor muscle differ-
entiates25 and is invaded by autonomic nerves.26 At this
stage, both LRIG2 and heparanase-2 were immunode-
tected within nerve fascicles located between muscle
bundles (Figures 3A–3D). LRIG2 was also weakly immuno-
localized in smooth-muscle bundles themselves (Fig-
ure 3A). Coimmunostaining with b3-tubulin, a neuronal
axonal cytoskeletal protein, demonstrated that LRIG2
appears to be localized in cells adjacent to neurons (Figures
3E–3G). These might be Schwann-like cells within pregan-
glionic parasympathetic nerves, the neurons of which
synapse with second-order neurons within intramural
ganglia.4 Furthermore, we detected LRIG2 transcripts in
12-week-postconception human fetal bladders and ureters,
but not in kidney tissue (Figure S4), whereas the three tran-
scripts of HPSE227 were detected in the bladder, but not in
ureter or kidney tissue. Heparanase-2 immunoreactivity
partially overlapped with b3-tubulin (Figures 3H–3J),
consistent with its being present in neurons themselves.
Evidence already implicates heparanase-1 in neural
biology,28–30 and its enzymatic activity is inhibited by
heparanase-2.10
Collectively, the evidence indicates that both LRIG2 and
heparanase-2 are required for normal LUT innervation7, 2013
Figure 3. Immunohistochemistry of a Normal Urinary Bladder
at 12 Weeks of Gestation
(A–D) Bright-field images counterstained with hematoxylin (blue
nuclei).
(A) Immunodetection of LRIG2 (brown). Note the prominent
signal in a linear structure (arrows) betweenmuscle bundles (aster-
isks), which themselves show weaker LRIG2 immunoreactivity.
The scale bar represents 50 mm.
(B) Heparanase-2 immunodetected in a nerve-like structure
between muscle bundles.
(C) The linear structure contains components with b3-tubulin
immunoreactivity, an axonal protein, thus confirming that it is
a nerve.
(D) Detrusor muscle bundles express a-smooth muscle actin.
(E–J) High-power dark-field images of an area of nerve similar to
that in the outlined box in (C). LRIG2 and b3-tubulin immunore-
activity (white) are depicted in (E) and (F), respectively. The color
merged image (G) shows that the signal for LRIG2 (red) is generally
discrete from the signal (green) for b3-tubulin; given that the latter
is an axonal marker, LRIG2 might be mainly localized in neural
support cells, the exact nature of which remains to be established.
Heparanse-2 and b3-tubulin immunoreactivity (white) are de-
picted in (H) and (I), respectively. The merged image (J) shows
that the signal for heparanase-2 partially overlaps with that of
b3-tubulin to generate a yellow color. Histology, incorporating
5 mm paraffin sections of paraformaldehyde-fixed tissues, was
undertaken with human fetal tissue collected with ethical
approval under the Codes of Practice of the UK Human Tissue
Authority. Endogenous peroxidise was quenched by incubation
with hydrogen peroxide, and antigen retrieval was undertaken
by heating at 95C for 5 minutes in sodium citrate (pH 6). The
primary antibodies used were goat anti-a-smooth muscle actin
The Americand/or neural function. It is curious why loss-of-function
mutations in these two genes, expressed more widely in
the peripheral nervous system, should result in a specific
phenotype confined to elimination and facial expression.
Mild degrees of dysfunctional bladder voiding, including
overactivity, are common in otherwise healthy children
after the age when conscious bladder control has normally
been acquired.18 Nonsyndromic VUR, which affects 1% of
children, is commonly familial.3 We speculate that the
biological pathways mediated by LRIG2 and the hepara-
nases might be implicated in these common disorders of
elimination.Supplemental Data
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